Literature DB >> 17305791

Diabetes risk in British adults in mid life: a national prevalence study of glycated haemoglobin.

C Thomas1, E Hyppönen, C Power.   

Abstract

AIMS: Information on the population at risk of developing Type 2 diabetes in the UK is scarce. We used data from the 1958 British birth cohort to estimate geographical and socio-economic variations in HbA(1c) in mid life.
METHODS: Participants (n = 7799) born in England, Scotland and Wales and currently living in the UK. Individuals were classified according to the presence of Type 2 diabetes and by thresholds of HbA(1c). HbA(1c)> or = 5.5 was used as an indicator for possible subclinical alterations in glucose metabolism.
RESULTS: The majority of the population had HbA(1c) < 5.5% (79.3%); 16.7% had HbA(1c) 5.5-5.9%, 2.0% 6.0-6.9% and 0.6% had HbA(1c)> or = 7.0%. Individuals from manual socio-economic groups and those living in the East of England and Scotland had a higher prevalence of HbA(1c) at or above the upper normal range (5.5%).
CONCLUSIONS: Estimates from this nationwide sample suggest that a proportion of Britons are likely to have subclinical alterations in glucose metabolism by their mid 40s, and this proportion is greater in some socio-economic groups and geographical regions than in others.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17305791     DOI: 10.1111/j.1464-5491.2006.02055.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  2 in total

1.  Changes in BMI, duration of overweight and obesity, and glucose metabolism: 45 years of follow-up of a birth cohort.

Authors:  Chris Power; Claudia Thomas
Journal:  Diabetes Care       Date:  2011-07-20       Impact factor: 19.112

2.  Interaction between allelic variations in vitamin D receptor and retinoid X receptor genes on metabolic traits.

Authors:  Karani S Vimaleswaran; Alana Cavadino; Diane J Berry; Massimo Mangino; Peter Andrews; Jason H Moore; Timothy D Spector; Chris Power; Marjo-Riitta Järvelin; Elina Hyppönen
Journal:  BMC Genet       Date:  2014-03-19       Impact factor: 2.797

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.